StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Repatha (evolocumab by Quarter

Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide volume growth YoY (%) (%)

QuarterlyAnnual

Amgen Repatha (evolocumab: 35.0% in Q1 2026, down 6.0 pts from a year earlier.

Latest, Q1 2026
35.0%
Period ended Mar 31, 2026
Change on a year earlier
-6.0 pts
41.0% in Q1 2025
History
20 quarters
Since Q1 2020
Sources
20
Documents cited below

Where the Q1 2026 figure comes from

“Repatha ® (evolocumab) sales increased 34% year-over-year to $876 million in the first quarter, driven by 35% volume growth and 8% favorable changes to estimated sales deductions, partially offset by 7% lower net selling price.”

Source: Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗

Reported in Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRepatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide volume growth YoY (%) (%)Year on yearSource
Q1 2026Mar 31, 202635.0%-6.0 ptsForm 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 202531.0%–Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q2 2025Jun 30, 202536.0%-10.0 ptsForm 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 202541.0%-3.0 ptsForm 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗
Q3 2024Sep 30, 202441.0%-2.0 ptsForm 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202446.0%+9.0 ptsForm 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 202444.0%+10.0 ptsForm 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 202335.0%–Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 202343.0%-30.0 ptsForm 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 202337.0%-1.0 ptsForm 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 202334.0%-23.0 ptsForm 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q3 2022Sep 30, 202273.0%+31.0 ptsForm 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗
Q2 2022Jun 30, 202238.0%-11.0 ptsForm 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗
Q1 2022Mar 31, 202257.0%+15.0 ptsForm 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗
Q3 2021Sep 30, 202142.0%-18.0 ptsForm 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗
Q2 2021Jun 30, 202149.0%-20.0 ptsForm 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗

Cite this data

StockData. (2026). Amgen Repatha (evolocumab (%), quarterly Q1 2020–Q1 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-repatha-vol

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.